# Nabla Bio

> Nabla Bio is a Cambridge, Massachusetts biotech building AI plus wet-lab technology to design antibodies and protein therapeutics from scratch. Its Joint Atomic Modeling (JAM) platform generates de novo binders against historically undruggable membrane proteins like GPCRs, and the company has signed collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth over a billion dollars in potential payments.

- **Founded:** 2020
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Surge Biswas (Co-founder & CEO), Frances Anastassacos (Co-founder)
- **Team size:** ~22 employees
- **Products:** JAM (Joint Atomic Modeling), De novo antibody design platform, High-throughput functional screening
- **Notable:** Reported the first fully computationally designed antibody binders to the GPCR CXCR7 (ACKR3) and to Claudin-4 (CLDN4)., Reported the first computationally designed antibody GPCR agonists of any kind., Published research showing test-time compute ('introspection') scaling improves antibody design success.

## Products & services

- **JAM (Joint Atomic Modeling)** — A multimodal generative AI system trained on large protein sequence and structure datasets plus Nabla's own human-relevant lab measurements. It takes partial molecular context (a target or epitope) and 'autocompletes' the rest to design de novo antibodies, multispecifics, and other biologics.
- **De novo antibody design platform** — An integrated AI and wet-lab pipeline that designs antibody binders from scratch against challenging targets, with an initial focus on multipass membrane proteins like GPCRs, ion channels, and transporters.
- **High-throughput functional screening** — Massively parallel wet-lab technology that can characterize the binding properties of about 100,000 antibodies in roughly three weeks.

## Achievements

- Reported the first fully computationally designed antibody binders to the GPCR CXCR7 (ACKR3) and to Claudin-4 (CLDN4).
- Reported the first computationally designed antibody GPCR agonists of any kind.
- Published research showing test-time compute ('introspection') scaling improves antibody design success.
- Signed collaborations with AstraZeneca, BMS, and Takeda; the 2025 Takeda expansion alone carries >$1B in potential payments.
- Founder Surge Biswas created an early protein language model in George Church's Harvard lab.

## Latest updates

- **2025-10** — Signed a second collaboration with Takeda to advance AI-driven design of protein therapeutics, with potential payments exceeding $1 billion.
- **2025-05** — Published research on scaling test-time compute to design hundreds of functional GPCR-targeting antibodies.
- **2024-05** — Closed $26M Series A led by Radical Ventures and announced collaborations with AstraZeneca, BMS, and Takeda.

## Links

- Website: https://nabla.bio
- LinkedIn: https://www.linkedin.com/company/nabla-bio/
- Twitter/X: https://twitter.com/nablabio

---

Profile page: https://yespress.io/nabla-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-07